Fri, Jul 25, 2014, 11:23 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Arena Pharmaceuticals, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • This link is to the the infamous "Bas•. her's Handbook," a document which instructs hedge fund lackeys on directly how to damage stocks with misinformation campaigns.

    **** EVERYONE should read it to fully understand why the bashers are here. ****

    It is all part of their plan to bury this board in nonsense to interfere with real investors' ability to converse on the benefits of ARNA as a company.


    Sentiment: Strong Buy

  • TRx 9,316 v 8,058. up 15.6% NRx 7,422 v 6,228 up 19.1%

  • Symphony Belviq week ended 5/2 TRx 9,988 up from 9,316 7.2%, NRx 8,078 up from 7,422 or 8.8%

  • THIS IS HUGE !!!


    Sentiment: Strong Buy

  • I would like to let it be known that at 4:10 this afternoon I transmitted over to the SEC excel spreadsheet pages of trades made from 1 PM to 4PM wanting them to see the number of 100 share trades made in a row used to trade down the share price of Arena Pharm. I also explained that it would seem very strange that there would be so many trades of 100 shares in a row. There are numerous times that there were these type of transactions showing 5 in a row some 8 in a row and a couple of times even 10 in row. I also informed them that I was contemplating giving this info to a few law firms to see what their thoughts were. An individual from the SEC acknowledged back to me that I am not the first to lodge this type of complaint in reference to TRADING IN ARENA and that they have already taken this problem under advisement and are themselves monitoring the trading in this company. He also stated that since it was an active situation he could not go further. STAY TUNED!!!!!

  • - Don't respond to them
    - Don't thumb them up OR down

    Just completely ignore them. They crave attention due to their short man complexes. Let's all just act as if they don't exist and let them shrivel up in their boiler room cubicles. You know it is what they deserve.

  • Nashville – Lorcaserin is more effective in helping obese patients with type 2 diabetes achieve glycemic control than diet and exercise alone, data from a poster presented at the American Association of Nurse Practitioners 2014 meeting indicate.

    The phase 3 BLOOM-DM clinical trial looked at the effects of lorcaserin (Belviq, Eisai Pharmaceuticals) on weight loss, hemoglobin A1c levels and cardiometabolic risk factors.

    The study included 509 patients who were randomly assigned to either lorcaserin or placebo along with diet and exercise. All patients had hemoglobin levels between 7% and 10%, as well as similar fasting plasma glucose (FPG) levels. The researchers defined “responders” as patients who achieved the primary endpoint of weight loss of at least 5% at 52 weeks of treatment.

    Nearly twice as many patients with diabetes in the lorcaserin group achieved hemoglobin levels of less than 7% compared with the placebo group (50.4% vs. 26.3%), even if they did not lose weight, the researchers found.

    Measured from baseline, the mean change in FPG and hemoglobin levels in the lorcaserin was -38.1 mg/dL and -1.3, respectively, compared to -26.0 mg/dL and -1.0 in the placebo group.

    Those who responded to treatment had overall improved glycemic control and relied less on the use of antihyperglycemic medications compared with those who did not.

    When it came to cardiometabolic risk factors, the authors also noted an overall decrease in both systolic and diastolic blood pressure in all groups treated with either lorcaserin or placebo, aside from small increases in systolic BP noted at week 52.

    “Glycemic control was substantially improved despite minimal weight loss in lorcaserin non-responders,” the authors concluded. “This observation suggests potential weight-independent effects of lorcaserin on glycemia, which should be studied further.”

    Common adverse effects among the treatment arm were hypoglycemia, headache, back pain, cough and fatigue.

  • Scrips jump to highest week ever

    Total Obesity up 6.1%

    Q up 9.7% to 10.1k

    B up 10.2% to 12.3k

    Bel market share also rises again.

    Sentiment: Strong Buy

  • They join the cannabinoid 1 & 2 party late, lack the resources to devote to it and will fail to compete with the other larger BP's already working on it.

  • TRx 10,660 vs 10,615 NRX 8,505 vs 8,540.

  • Bel over 12k
    Bel up 23.8%

    Total obesity up 16.3%

    Q up only 11.97%

    P up 16.1%

    Belviq is beating all other obesity scrips week after week and is taking market share.

    Another reason why the talking heads are turning in favor of ARNA.

  • What we see now is that money is made on stocks by unscrupulous people who use psychological warfare to 'defeat' their opponents.

    People like vanmusicblues and spencer osborne (one in the same person) use nonstop SCARE TACTICS to demoralize longs into selling their shares. It is a standard method found in lao tzu's "The Art of War" and 'Sun Tzu and psychological warfare.'

    "Since warfare's beginning, military philosophers and strategists have recognized the necessity of "psychological operations" (a subset of propaganda, since PSYOP is generally directed at the enemy, while propaganda is additionally used on one's own). Sun Tzu wrote, "One need not destroy one's enemy. One need only destroy his willingness to engage." And Carl von Clausewitz wrote, "Killing the enemy's courage is as vital as killing his troops." How forces have gone about doing so demonstrates the full spectrum of wartime caginess and brutality, of ingenuity and comic ineptitude. "



    Sentiment: Strong Buy

  • MD's are already using Belviq with phen. That is how we get the evidence through the grapevine that 15%+ efficacy is what the trials will show among a large percent of participants.

    Here is the deal. Listen carefully...

    1. Belviq is already being written co-scripted with phen. Once the trial results are published, every MD who is paying attention will have the scientific justification for dual scripting. So, Belviq sales WILL increase right off the bat.

    2. Eisai will probably not be in a big rush to have a single pill formulation approved by the FDA. That would cost a lot of money and if Belviq sales are already positively impacted by the trials then why rush into it. Let the market reward the concept without going too far into additional costs.

    3. Now, some years down the road, Eisai may choose to submit for Bel-Phen with a timed release lorcaserin because THAT could serve to extend the patent life of Belviq.

    Just some thoughts. The most important idea here is that publication of the Bel-Phen trials will likely have an immediate impact as those patients who do NOT meet the 12 week efficacy threshold may simply have phen added to their regimen. So, fewer dropouts and more seriously obese patients get started on a dual script.

  • You did GOOD!

  • Belviq was released in June of 2013. The FDA's most recently released database is from the time period July 1, 2013 - September 30, 2013. Belviq had ZERO adverse events reported to the FDA during that time. Qsymia has been on the market for nine months longer than Belviq. During that same period Qsymia had 11 adverse events reported. Bupropion (one of the drugs in Contrave) had more than 20 adverse events reports. Yes, I know Qsymia and Bupropion had more patients taking the drug during that time. My point is more about Belviq. ZERO adverse events during their first quarter on the market. For those shorts sitting around waiting for someone to decide this drug is not safe, it is not going to happen.

  • Not sure exactly how one stumbles upon it, but here is the link...

  • pathetic. says a lot about the company and their tactics toward retail who know so very little

  • Nothing new in these articles. The significance is that Belviq will continue to get more and more exposure in the medical literature

    New pharmacological treatments for the management of obesity.
    Hurt RT, Edakkanambeth Varayil J, Ebbert JO - Curr Gastroenterol Rep - Jun 2014; 16(6); 394

    Obesity is quickly becoming the leading preventable cause of death in the USA. Over 60 obesity-related comorbidities exist which increase the complexity and cost of medical care in obese patients. Even a moderate weight loss of 5 % can reduce morbidity associated with these conditions. Lifestyle modification through caloric restriction and enhanced exercise and physical activity remain the first line treatment for obesity. The development of pharmacologic agents for the treatment of obesity has been challenged by both lack of efficacy and serious adverse side effects leading to their removal from market. Two new agents were recently approved by the US Food and Drug Administration to complement lifestyle modification in obese and overweight patients and one obesity-related comorbidity). Lorcaserin is a novel serotonin 5-HT2C selective agonist which has been shown in three phase III studies to significantly reduce weight and cardiovascular risk factors such as diabetes. Phent/topiramate extended release (ER) is a novel combination of two agents which have individually been shown to significantly reduce weight. The combination agent phent/topiramate ER has been shown to reduce weight in overweight and obese subjects in a number of studies. This article reviews the pharmacology, clinical efficacy, and safety of these new agents compared to past and other presently available medications for the treatment of obesity.

    NOTE: "Lorcaserin....shown to significantly reduce weight and cardiovascular risk factors such as diabetes."

    This is a factual statement that will continue to increase in its dissemination...because the science will prevail.



    Sentiment: Strong Buy

  • posted 7/16/2014 8:14:34 AM by pharmionphil

    Re: Why a PR for CB-2 patent?///Primary patent

    Rare composition of matter patents deserve a PR. The majority of patents are secondary and more easily challenged by generic manufacturers. Composition of matter patents cover not only the compound itself but any variation of it such as hydrates,salts,or esters. They stop any competitor from attempting to develop the same compound generically--whatever the process, route of administration or formulation. It is the strongest protection for APD371 and extends 20 years(original patent filed in 2010)

    Non-opiod pain relief is a monster market indeed and APD371 is working its way thru phase1a. One big potential catalyst for sure of many here. Good luck.

4.77-0.08(-1.65%)Jul 25 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.